2019 IPO

Brickell Biotech Stock

Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.

Sign up today and learn more about Brickell Biotech Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Brickell Biotech Stock

Brickell Biotech, Inc., a Delaware corporation, is a development-stage pharmaceutical company focused on the acquisition, development and commercialization of innovative drug therapies for the treatment of skin diseases.

Funding History

July 2010$6.2M
February 2013$7.0M
August 2014$2.2M
February 2015$10.0M


Co-Founder and President

Reginald Hardy

President and Chief Scientific Officer

Patricia Walker

Chief Financial Officer

Jerry Coombs

Vice President, New Product Development

Charles Betlach

Vice President, Product Development

Elizabeth Hussey

Vice President, Chemistry, Manufacturing, and Controls

John Koleng

Co-Founder and Vice President, Operations

Andrew Sklawer

Senior Vice President, Global Regulatory Affairs

Deepak Chadha


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: